JP Morgan Chase’s Pacira BioSciences PCRX Stock Holding History

JP Morgan Chase’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-380,000	Closed	-$16.3M	–	5962
2018 Q4	$16.3M	Hold	380,000	–	–	﹤0.01%	1633
2018 Q3	$18.7M	Buy	380,000 +230,000	+153%	+$9.94M	﹤0.01%	1713
2018 Q2	$4.81M	Buy	+150,000	New	+$5.18M	﹤0.01%	2712
2018 Q1	–	Sell	-108,300	Closed	-$4.94M	–	5565
2017 Q4	$4.94M	Buy	108,300 +98,300	+983%	+$3.9M	﹤0.01%	2685
2017 Q3	$387K	Sell	10,000 -90,000	-90%	-$3.62M	﹤0.01%	3912
2017 Q2	$4.77M	Buy	+100,000	New	+$4.64M	﹤0.01%	2503

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase's PCRX Position: Q1 2026 in Review

JP Morgan Chase reduced its Pacira BioSciences (PCRX) stake by 17% in Q1 2026, selling an estimated $1.07M and leaving 240,369 shares worth $5.59M. The position accounts for ﹤0.01% of the portfolio, ranked #3222.

JP Morgan Chase first reported a position in PCRX in Q2 2013 and has held it in 52 quarters since. The position peaked at $31.9M in Q2 2014. 241 funds tracked by Wall St. Rank hold PCRX as of Q1 2026.

JP Morgan Chase held 240,369 shares of Pacira BioSciences worth $5.59M as of Q1 2026.
JP Morgan Chase sold 48,282 Pacira BioSciences shares in Q1 2026, an estimated $1.07M.
Pacira BioSciences made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #3222 holding.
JP Morgan Chase first reported a position in Pacira BioSciences in Q2 2013 and has held it in 52 quarters since.
JP Morgan Chase's Pacira BioSciences position peaked at $31.9M in Q2 2014.
241 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.